Mode
Text Size
Log in / Sign up

Multimodal Bronchoscopic Therapy May Help Tracheobronchial Amyloidosis StenosisRare Airway Condition Treated With Multimodal Bronchoscopy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider multimodal bronchoscopic therapy for TBA stenosis, but recognize single-case evidence limits generalization.

This is a case report and literature review focused on the management of tracheobronchial amyloidosis, a rare condition. The authors describe a 56-year-old man with primary, recurrent, and residual airway stenosis who underwent multimodal bronchoscopic intervention. The intervention combined balloon dilatation, forceps debridement, diode laser ablation, low-temperature plasma radiofrequency ablation (LTP-RFA), and cryotherapy.

Over 12 months of follow-up, the patient's symptoms improved significantly, and both endoscopic and radiographic status improved. No effect sizes, absolute numbers, or p-values were reported for these outcomes. The report notes that LTP-RFA is a novel or rarely reported intervention for this condition.

Safety data were not reported, including adverse events, serious adverse events, discontinuations, and tolerability. The authors acknowledge limitations inherent to a case report, including the small sample size (n=1). Funding and conflicts of interest were not reported.

The authors suggest this case may serve as a reference for individualized management of tracheobronchial amyloidosis. However, because this is a single case, the results cannot be generalized to the broader population, and no causal conclusions can be drawn.

This is a case report describing one 56-year-old man with tracheobronchial amyloidosis, a rare condition where abnormal proteins build up in the breathing tubes. He was treated with a combination of bronchoscopic procedures: balloon dilatation, forceps debridement, diode laser ablation, low-temperature plasma radiofrequency ablation (LTP-RFA), and cryotherapy. The report covered treatment of primary, recurrent, and residual airway stenosis.

Over 12 months of follow-up, his symptoms improved significantly. Endoscopic and radiographic findings also improved. No side effects or safety problems were reported in the available information.

Because this is a single case report, the results cannot be generalized to other people with this condition. It does not prove that any one of these treatments caused the improvement, and there was no comparison group. The authors present it as a reference for individualized management, and note that LTP-RFA is a novel and rarely reported option for this disease.

Readers should view this as early, descriptive evidence. It may help doctors consider treatment options, but it is not a substitute for a clinical trial. Anyone with tracheobronchial amyloidosis should discuss care with their specialist.

What this means for you:
A single case report describes symptom and airway improvement after combined bronchoscopic treatments for this rare condition.

Common questions

What is tracheobronchial amyloidosis?

It is a rare condition where abnormal proteins build up in the breathing tubes, which can cause narrowing and symptoms. This report describes one 56-year-old man with the condition who was treated with several bronchoscopic procedures.

What treatments did the patient receive?

He received a combination of bronchoscopic procedures: balloon dilatation, forceps debridement, diode laser ablation, low-temperature plasma radiofrequency ablation (LTP-RFA), and cryotherapy. The report covered treatment of primary, recurrent, and residual airway stenosis.

Did the treatment work?

Over 12 months of follow-up, his symptoms improved significantly, and endoscopic and radiographic findings also improved. Because this is a single case report, these results cannot be generalized to other patients.

Were there any side effects?

The available information does not report any side effects, serious adverse events, or treatment discontinuations. This does not mean side effects cannot occur; it means they were not described in this case report.

Can I get this treatment for my condition?

This is a single case report, so it does not prove the treatment works for everyone. LTP-RFA is described as a novel and rarely reported option for this condition. Talk with your specialist about whether any of these procedures might be appropriate for you.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Tracheobronchial amyloidosis (TBA) is a rare airway disorder characterized by abnormal deposition of amyloid protein in the submucosa and muscular layer of the tracheobronchial tree. Clinical manifestations are nonspecific, and the disease is frequently misdiagnosed as chronic obstructive pulmonary disease, bronchial asthma, or airway malignancy. No standardized diagnostic and treatment guidelines exist, and bronchoscopic interventions have become the preferred approach for relieving airway obstruction. We report a 56-year-old man with TBA presenting with a 12-year history of recurrent cough, sputum production, and dyspnea. Chest computed tomography (CT) revealed diffuse bronchial wall thickening with calcification and irregular luminal narrowing, with obstructive pneumonia and atelectasis in the right middle and lower lobes. Bronchoscopy demonstrated diffuse mucosal thickening with nodular hyperplasia and marked luminal stenosis. Congo red staining was positive with apple-green birefringence under polarized light, confirming localized TBA. The patient underwent three stages of multimodal bronchoscopic intervention over 12 months—comprising balloon dilatation, forceps debridement, diode laser ablation, low-temperature plasma radiofrequency ablation (LTP-RFA), and cryotherapy—to treat the primary, recurrent, and residual airway stenosis. Following serial treatments, the patient's symptoms improved significantly, with endoscopic and radiographic improvement. This case represents one of the few reports of LTP-RFA application in TBA. We review the recent literature on TBA treatment modalities and outcomes, providing a reference for individualized TBA management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.